

ForPatients

by Roche

Triple Negative Breast Cancer Ovarian Cancer

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT03101280 2016-002610-47
WO39409

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase Ib, open-label, non-randomized study in patients with previously treated advanced ovarian or endometrial cancer (Part 1) and platinum-sensitive ovarian cancer or triple-negative breast cancer (TNBC) (Part 2) to investigate the dose, safety, pharmacokinetics, and preliminary efficacy of rucaparib in combination with atezolizumab. The study is conducted in 2 parts: a Dose-Finding Phase (Part 1) and a Dose-Expansion Phase (Part 2)

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03101280 2016-002610-47 WO39409
Trial Identifiers

Eligibility Criteria:

Gender
Female

Age
≥ 18 Years

Healthy Volunteers
No
